EGFR and non-small cell lung carcinoma: When considering results per ethnic subgroup, activating EGFR mutations were detected in 44%, 28% and 14% of non-squamous metastatic NSCLC tumours in Asian, black and white patients, respectively (p = 0.001) and ALK or ROS1 re-arrangement were detected in 22%, 3% and 17%, respectively (p = 0.2).